Journal
FRONTIERS IN MEDICINE
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2023.1192070
Keywords
glioblastoma; flavivirus; oncolytic virus; ZIKV; DENV; immunovirotherapy
Categories
Ask authors/readers for more resources
During a Zika virus outbreak in Brazil, a glioblastoma patient showed symptoms similar to an arbovirus-like infection, and after the infection resolved, the glioblastoma regressed without recurrence. This clinical response has continued for 6 years.
Glioblastoma is the most frequent and aggressive primary brain cancer. In preclinical studies, Zika virus, a flavivirus that triggers the death of glioblastoma stem-like cells. However, the flavivirus oncolytic activity has not been demonstrated in human patients. Here we report a glioblastoma patient who received the standard of care therapy, including surgical resection, radiotherapy and temozolomide. However, shortly after the tumor mass resection, the patient was clinically diagnosed with a typical arbovirus-like infection, during a Zika virus outbreak in Brazil. Following the infection resolution, the glioblastoma regressed, and no recurrence was observed. This clinical response continues 6 years after the glioblastoma initial diagnosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available